- Home
- SNCY vs ABUS Comparison
SNCY vs ABUS Comparison
Compare SNCY & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCY
- ABUS
- Stock Information
- Founded
- SNCY 1982
- ABUS N/A
- Country
- SNCY United States
- ABUS United States
- Employees
- SNCY N/A
- ABUS N/A
- Industry
- SNCY Air Freight/Delivery Services
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- SNCY Consumer Discretionary
- ABUS Health Care
- Exchange
- SNCY Nasdaq
- ABUS Nasdaq
- Market Cap
- SNCY 670.1M
- ABUS 617.3M
- IPO Year
- SNCY 2021
- ABUS N/A
- Fundamental
- Price
- SNCY $11.58
- ABUS $3.48
- Analyst Decision
- SNCY Buy
- ABUS Strong Buy
- Analyst Count
- SNCY 7
- ABUS 4
- Target Price
- SNCY $19.29
- ABUS $5.50
- AVG Volume (30 Days)
- SNCY 823.9K
- ABUS 953.7K
- Earning Date
- SNCY 05-05-2025
- ABUS 03-27-2025
- Dividend Yield
- SNCY N/A
- ABUS N/A
- EPS Growth
- SNCY N/A
- ABUS N/A
- EPS
- SNCY 0.96
- ABUS N/A
- Revenue
- SNCY $1,075,739,000.00
- ABUS $6,171,000.00
- Revenue This Year
- SNCY $10.53
- ABUS N/A
- Revenue Next Year
- SNCY $10.09
- ABUS $61.99
- P/E Ratio
- SNCY $12.08
- ABUS N/A
- Revenue Growth
- SNCY 2.49
- ABUS N/A
- 52 Week Low
- SNCY $9.22
- ABUS $2.30
- 52 Week High
- SNCY $18.59
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- SNCY 28.43
- ABUS 57.45
- Support Level
- SNCY $12.36
- ABUS $3.20
- Resistance Level
- SNCY $14.30
- ABUS $3.45
- Average True Range (ATR)
- SNCY 0.64
- ABUS 0.15
- MACD
- SNCY -0.05
- ABUS 0.03
- Stochastic Oscillator
- SNCY 11.26
- ABUS 72.73
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.